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1. Introduction 
The HIV epidemic continues to be a major world-wide health and human problem as 
reflected in the AIDS epidemic updates from the World Health Organization (WHO). 
Highly active antiretroviral therapy (HAART) has improved health management, especially 
in developed countries, since it was first introduced in the mid-1990s. However, access to 
antiretroviral therapy in developing countries has been limited. Developing an effective 
vaccine is an on-going mission, the success of which depends on understanding key aspects 
of the immune response to HIV. Hence, studying the genetic components of the immune 
response to the HIV virus is essential.  
The existence of genetic factors that modulate immune response to infectious diseases was 
described more than 10 years ago (Hill, 1998). We recommend various recent and extensive 
reviews that have focused on the immunobiology of HIV infection (Tripathi and Agrawal, 
2007), the immune response to HIV (Chakrabarti and Simon, 2010; Miyazawa, et al. 2008) 
and specifically the innate response (Borrow and Bhardwaj 2008). Innate and adaptive 
immune responses play a decisive role during the initial stages of HIV infection and will 
also affect the progression of the disease. Definitive evidence that host genetics plays a role 
in the immune response to HIV is the fact that HIV-1 infection does not always progress to 
AIDS. A small percentage (less than 0.2%) of HIV-1 sero-positive patients is able to control 
the infection, meaning that they can maintain a viral load of fewer than 50 copies of HIV-1 
RNA per ml over 10 years. These patients have been given different names: HIV controllers, 
HIV elite controllers, long-term non-progressors (LTNPs) or natural virus suppressors 
(Chakrabarti and Simon, 2010).  
This chapter focuses on the influence exerted on HIV infection by the human major 
histocompatibility complex (MHC) system, also known as the human leukocyte antigen 
(HLA) system. The effect of the MHC system on HIV infection is crucial for development of 
an effective vaccine. We recommend several reviews on this subject that complement the 
present monograph (Carrington and O'Brien, 2003; Stephens, 2005; Miyazawa et al. 2008; 
Kaur and Mehra, 2009; Singh and Spector, 2009). In this chapter, we will first describe the 
most important and relevant characteristics of the MHC, then we will review the recent 
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literature on the influence of the MHC on both horizontal and vertical (mother-to-infant) 
transmission. Finally, we highlight the molecular basis of the most important associations 
currently believed to exist between MHC and HIV transmission, with special emphasis on 
recent theories about how the MHC shapes the cytotoxic T cell (CTL) response and its 
relation to the appearance of HIV escape variants.  
2. The human Major Histocompatibility Complex (MHC) 
The MHC is located on the short arm of chromosome 6 and contains a large number of 
genes related to immune system function. Some MHC genes encode proteins that help to 
distinguish self and non-self components. They were first discovered in transplantation 
immunology and the gene products were called antigens. There are 3 major classes: Class I 
molecules are encoded by classical genes (A-C) and non-classical genes (E-G). Class II 
molecules are encoded by classical genes (DP, DQ, DR) and non-classical ones (DM, DOA, 
DOB). Class III molecules include components of the complement system and other immune 
system molecules. 
 
 
Fig. 1. Schematic of the Human Major Histocompatibility Complex (MHC). 
2.1 The human MHC class I molecules 
The class I protein comprises a ǂ-polypeptide chain that associates with the invariant ǃ 
chain ǃ2 microglobulin (ǃ2m). MHC class I molecules (A, B, C) present peptides mainly 
from inside the cell; for example, they present viral peptides when these are found in the cell 
cytoplasm. These peptides are produced by the proteasome, which breaks down proteins to 
fragments approximately 9 amino acids (AA) long. Viral, bacterial or self-peptides will be 
displayed in the binding cleft of the MHC molecule on the cell surface, in a process known 
as antigen presentation; the displayed fragments are recognized by CD8+ or cytotoxic T cells 
(CTLs), which destroy infected cells. Each person expresses 3 MHC class I molecules (A, B, 
C) from each chromosome. Most nucleated cells express class I molecules. Many viruses 
reduce the expression of MHC class I molecules to hamper the immune response. This is the 
case of HIV, which down-regulates CD4 and HLA class I expression through its Nef protein 
(Greenberg et al., 1998). Compared to the HLA-A and -B loci, the HLA-C locus shows less 
polymorphism. In addition HLA-C proteins are expressed at lower levels on the cell surface, 
and seem to bind primarily to natural killer immunoglobulin-like receptors (KIRs). 
Class Ia molecules show greater polymorphism and wider tissue distribution than class Ib 
molecules. Of the non-classical HLA class I molecules involved in HIV infection, HLA-G is 
the best studied. Alternative splicing of HLA-G gives rise to 7 isoforms, 4 membrane-bound 
(HLA-G 1-4) and 3 soluble (HLA-G 5-7). G5 and its membrane-bound counterpart G1 are 
proteolytically released from the membrane to give rise to the major soluble forms of HLA-
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G. HLA-G is expressed in placental trophoblast cells as well as in the thymus, pancreas and 
other tissues. Its ectopic expression has been reported under various pathological 
conditions, including viral infections. It is currently accepted that HLA-G molecules exert 
immunosuppressive functions (Fainardi et al., 2011). 
2.2 The human MHC class II molecules 
These are encoded by three classical genes (HLA-DP, -DQ and -DR) and two non-classical 
ones (HLA-DM and -DO) (reviewed by (Handunnetthi et al., 2010)). This region includes 
other genes implicated in antigen processing, such as the genes encoding transporter 
associated with antigen processing protein 1 and 2 (TAP1 and TAP2). Class II molecules 
comprise  andchains. Their expression is restricted mainly to thymic epithelial cells and 
bone marrow-derived antigen-presenting cells. The latter include B cells, macrophages (M) 
and dendritic cells (DCs). Differentiation of B cells into plasma cells, as well as 
differentiation of dendritic cells, is accompanied by down-regulation of MHC class II 
expression. On the contrary activation of T cells up-regulates their expression of class II 
molecules. 
In the HLA-DR sub-region the gene DRA encodes 1 unpolymorphic  chain with only 1 
common and 2 very rare alleles. The  chain is encoded by the very polymorphic DRB1 
gene. There are 3 DRB1 paralogue genes: DRB3, DRB4 and DRB5, however DRB1 is 
expressed at a level five times higher than them. The MHC class II is highly polymorphic. 
For instance, there are over 500 different HLA DRB1 alleles in humans. The DRB loci are 
classified into 5 major haplogroups according to the number of functional genes (DRB1, 3, 4 
and 5) and pseudogenes (DRB2, 6, 7, 8, 9) that are present (Table I).  
 
Halogroup Genes and Pseudogenes 
DR1 DRB1, DRB6 and DRB9 
DR8 DRB1 and DRB9 
DR51 DRB1, DRB5, DRB6 and DRB9 
DR52 DRB1, DRB2, DRB3 and DRB9 
DR53 DRB1M DRB4M DRB7, DRB8 and DRB9 
Families of DRB1 allelic lineage Genes 
DR1 HLA-DRB1*01 and *10 
DR8 HLA-DRB1*08 
DR51 HLA-DRB1*15 and *16 
DR52 HLA-DRB1*03, *11, *13 and *14 
DR53 HLA-DRB1*04, *07 and *09 
Table 1. DRB loci classification in halogroups and DRB1 families. 
Classical class II MHC genes are: 
HLA-DP: ǂ-chain encoded by the HLA-DPA1 locus (16 alleles) and ǃ-chain encoded by the 
HLA-DPB1 locus (118 alleles). 
HLA-DQ: ǂ-chain encoded by the HLA-DQA1 locus (25 alleles) and ǃ-chain encoded by the 
HLA-DQB1 locus (72 alleles).  
HLA-DR: ǂ-chain encoded by the HLA-DRA locus and 4 ǃ-chains encoded by the HLA-
DRB1, DRB3, DRB4, DRB5 loci. 
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The expression of MHC class II genes is tightly regulated, primarily at the transcriptional 
level. Their promoter contains regulatory elements collectively called the “SXY module”, to 
which various proteins bind, including regulatory factor X (RFX) and the class II 
transactivator (CIITA) (Handunnetthi et al., 2010). Induction of CIITA and subsequent 
expression of the MHC class II isotype HLA-DR are hallmarks of CD4+ T cell activation 
which, paradoxically, favors HIV replication. Interestingly, CIITA is able to inhibit HIV-1 in 
infected cells by blocking the function of the viral transactivators Tat and Tax (Tosi et al., 
2009). 
A key question about the influence of MHC on infectious disease is whether allele-specific 
sequence variation that affects the level of expression of HLA proteins can lead to class II-
associated diseases. For instance, transcripts in resting peripheral B cells have been reported 
to be more abundant within the DR52 haplogroup than within the DR53 haplogroup. A vast 
number of self-antigens are expressed at high levels in the thymic epithelium. It is 
postulated that a general reduction of self-antigen expression in the thymus could result in 
loss of central tolerance, meaning that thymocytes with excessive reactivity to self-antigens 
escape elimination. Does this increase susceptibility to infectious diseases? In the case of 
HIV, it seems that MHC-II presentation, at least by monocytes/macrophages, is preserved 
during infection (Woc-Colburn et al., 2010).  
Aside from the genes encoding the major antigens, a large number of other genes are located 
in the HLA complex (Fig. 1), many of which are involved in immune function. One 
significant characteristic of the HLA system is its tremendous polymorphism in the human 
population: there are many different alleles for each locus (ImmunoGeneTics HLA database: 
http://www.ebi.ac.uk./imgt/hal/atats.html). This implies that the chance of two unrelated 
individuals having identical HLA molecules on all loci is very low.  
3. Historical perspective: HLA-disease association studies and HIV infection 
The first reviews of HLA association with disease are from the late 1970s (Thomson and 
Bodmer, 1979) and early 1980s (Svejgaard et al., 1983), followed by other studies on HLA 
susceptibility to HIV infection (Scorza Smeraldi et al. ,1986; Just, 1995; Fauci, 1996; Buchacz 
et al. 1998) . 
HLA genes exhibit “linkage disequilibrium”, meaning that they are found together on the 
same chromosome at a higher frequency than expected according to their recombination 
distance. They are defined as a so-called “extended haplotype” or combination of alleles that 
are transmitted together as a unit. As with any gene frequently found in linkage 
disequilibrium with others, it is difficult to identify the specific HLA gene that is responsible 
for a given association observed in a population (Svejgaard et al., 1983). 
Studies of HLA associations with infectious diseases must separate HLA effects from many 
confounding factors, which are other factors that independently affect the risk of 
developing the disease. If the prevalence of these other factors differs between the groups 
being compared, they will distort the observed association. In the case of HLA/HIV 
associations, confounding factors include the ethnicity of the population studied, the 
frequencies of the HLA alleles detected and the resolution of the typing methods used. HLA 
associations are considered to be “consistent” when a similar or equivalent association is 
observed across different ethnic groups (Tripathi and Agrawal, 2007). 
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3.1 HIV associations and ancestral haplotypes 
Initial association analyses focused on ancestral haplotypes. An increased frequency of C4 
null alleles was found in HIV-infected individuals, which could in fact reflect an indirect 
association with a discrete number of ancestral haplotypes (Cameron et al., 1990). At that 
time a series of studies focused on the A1-B8-DR3-DQ2 haplotype, also known as the 8.1 
ancestral haplotype, which has been implicated in disease susceptibility (McNeil et al., 1996; 
Price et al., 1999). In addition, the HLA-B27 allele was found to be related to slow HIV 
disease progression (McNeil et al., 1996). Closer analysis of ancestral haplotypes points to a 
direct role of HLA-B35 in rapid HIV progression, and this allele is thought to be associated 
with disease susceptibility (Flores-Villanueva et al., 2003).  
3.2 HIV infection and HLA frequencies of individual alleles 
The proliferation of studies on associations between HLA frequencies and HIV infection 
made it clear to experts that it would be necessary to establish uniform research standards, 
such as more concrete definitions of HIV disease and its progression (Mann et al., 1992). 
Focusing on particular aspects of the disease, researchers were able to study a cohort of 106 
homosexual men from Amsterdam and correlate certain alleles with different aspects of HIV 
pathogenesis, including skin rash (HLA-B62), rapid decline of CD4+ T lymphocytes to < 
200/microL (HLA-B35), AIDS-related Kaposi's sarcoma (HLA-DR1) and opportunistic 
infections (HLA-DR3 and DQ2) (Klein et al., 1994). HLA disease associations studies were 
performed in different populations, such as in India (Shankarkumar, 2004), south India 
(Selvaraj et al., 2006) and southern Africa (Lombard et al., 2006). 
An important milestone in demonstrating that HIV-1 disease progression is associated with 
MHC genes was the discovery of HLA concordance between hemophilic siblings: pairs that 
shared one or two haplotypes were significantly concordant in CD4+ T cell decline and 
AIDS status within 5 years of seroconversion, while no concordance was found in pairs 
sharing no haplotypes. This is strong evidence that HLA is a determining factor or at least a 
relevant marker of disease progression. 
The expression level of HLA-G during HIV infection was found to be higher in monocytes 
from patients under HAART than from untreated individuals. Similarly, T cells from 
infected individuals express HLA-G. Different HLA-G alleles have been associated with 
protection (G-0105N9) and susceptibility (G-010108) (Fainardi et al. 2011). 
Viral load is an important factor determining the progression of HIV-1 infection. The initial 
peak of infection is followed by a period when the level remains relatively stable; the level 
during this period is called the “viral load set point” (VLS). A recent study addressed the 
influence of genetic factors, including HLA genotype, on the VLS (Saathoff et al., 2010). The 
study population was from Tanzania and was composed of three groups: female bar 
workers and females and males from the general population. HLA alleles were classified as 
protective (A*0205, B*5801, B*8101, B*4201, B*5703), harmful (B*5802, B*4501, B*1801 and 
B*1503) or neutral (all others). The prevalence of elevated viral load was 40% lower among 
individuals with protective alleles than among those with neutral ones. The major 
conclusion from this study is that male gender and possessing harmful HLA alleles are 
associated with higher VLS.  
HLA class II molecules are involved in presenting antigens to CD4+ T cells, which are 
central for establishing helper T responses. The HLA class II allele DRB1*1303 was 
associated with low plasma viral load in a cohort of 426 black South African females infected 
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with HIV-1 clade C. This association was confirmed in a larger cohort of 1436 male European 
Americans infected with HIV-1 clade B, demonstrating that the association was independent 
of ethnicity and viral subtype. Whether the protective effect exerted by this allele is due to the 
development of CD4+ T cell responses has yet to be shown (Julg et al., 2010). 
3.3 Advantage of heterozygous individuals 
Heterozygosity of MHC genes has long been thought to confer an advantage in the battle 
against infectious agents, and possessing different alleles at class I and II loci should 
therefore represent a benefit for HIV-infected individuals. Carrington et al. (Carrington et 
al., 1999) corroborated this key immune system dogma by studying HIV infection. They 
found that maximum heterozygosity of HLA-A, -B, and -C genes delayed progression to 
AIDS, while individuals who were homozygous at one or more loci progressed rapidly to 
AIDS. Furthermore, they were able to conclude that B*35 and Cw*04 were consistently 
associated with rapid development of AIDS in Caucasians. This work led to the proposal of 
a “heterozygote advantage and B*35-Cw*04 disadvantage theory" (Carrington et al., 1999). 
In subsequent work, the researchers studied the role of TAP genes and HLA supertypes in 
resistance to HIV infection. They found that the B*35 Px alleles were a risk factor, while the 
presence of alanine at position 665 in TAP2 was associated with resistance. Whether this 
resistance was due to a higher efficiency in transporting peptides, or was a consequence of 
linkage disequilibrium, was not resolved (Liu et al., 2003). Further studies have sought to 
consolidate our understanding of HLA-B35 alleles as risk factors, and have extended the 
findings in Caucasians to other populations (Shankarkumar et al., 2003). 
3.4 HLA supertypes  
Several studies have focused on the analysis of HLA supertypes (Sidney et al., 2008), in 
which HLA alleles are functionally classified according to their peptide-binding specificities 
(MacDonald et al., 2001). An attempt was made to group different HLA-B antigens 
(identified in patients by serology) according to their peptide-anchoring pockets, in order to 
determine whether the abovementioned associations could be explained by differences in 
the peptide repertoire presented by those molecules (Itescu et al., 1995). Later on, it was 
proposed that HIV adapts to the most frequent alleles in the population, implying that the 
expression of rare supertypes confers an advantage (Trachtenberg et al., 2003). 
3.5 Modern theories  
A recent study that, in our opinion, is an important breakthrough in the field, proposed that 
it is not the contribution of only one “relevant” allele that governs disease susceptibility but 
rather the sum of small contributions from several alleles (Leslie et al., 2010). The authors of 
that study justified their reasoning based on the fact that after excluding subjects expressing 
any of the important HLA-B class I alleles that strongly affect HIV control (B*57, B*58, and 
B*18), HLA-B alleles continued to play the dominant role in the observed progression (Leslie 
et al., 2010). If true, this idea would help reconcile some of the disparities reported in the 
literature. 
4. Vertical (mother-to-child) transmission of HIV-1  
Perinatal HIV-1 infection constitutes a significant global health problem and prevention of 
transmission is a high public health priority (Matt and Roger, 2001; Ahmad, 2010; UNAIDS, 
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2010). Much progress has been made in the development and implementation of strategies 
designed to interrupt vertical transmission. Antiretroviral therapy in HIV-infected pregnant 
women has significantly reduced the rate of mother-to-child transmission in developed 
countries down to 1% (Coovadia, 2004). In developing countries, however, many women 
still have limited access to antiretrovirals, and HIV-1 infection in children remains a major 
concern, with approximately 500,000 new HIV-1 infected infants born every year worldwide 
(Ahmad, 2010; UNAIDS, 2010). Prevention of maternal-fetal transmission of HIV-1 is 
therefore a global priority, especially in developing countries. 
Several lines of evidence suggest that host genetic factors are important determinants of 
both susceptibility to vertical transmission of HIV-1 and subsequent progression of AIDS in 
children (Matt and Roger, 2001). The identification of genetic markers linked with 
transmission and disease progression can help to define risk factors associated with vertical 
transmission and provide new insights into HIV-1 pathogenesis that can help in the 
development of an effective HIV-1 vaccine. 
In addition, pediatric HIV infection offers a good opportunity to investigate the influence of 
host genetics on the evolution of HIV, since the virus has first been in contact with the 
mother’s immune system and is then transmitted to a genetically related individual.  
In children with perinatally acquired HIV-1 infection, the expression of clinical and 
immunologic signs of disease seems to follow a bimodal distribution. At the beginning of 
the original HIV epidemic in the 1980s and 1990s, approximately 15–20% of infected infants 
showed an early and severe course of disease and died within the first 2 years of life. The 
remaining children progressed more slowly and had a less severe course, surviving an 
average of 8 years or more (Blanche et al., 1994). Today, children perinatally infected with 
HIV-1 reach adolescence, largely because of advances in treatment over the past 10 years 
(Dollfus et al., 2010). 
4.1 Routes of vertical HIV transmission 
HIV-1 vertical transmission occurs mainly during the following stages (Ahmad, 2010):  
1. prepartum, due to transplacental passage in utero,  
2. intrapartum, due to exposure of infant skin and mucus membranes to maternal blood 
and vaginal secretions during delivery, and  
3. postpartum, due to exposure to contaminated breastmilk during nursing  
In the absence of prophylactic treatment, it is estimated that one-third of children are 
infected in utero (prepartum) and two-thirds are infected intrapartum or postpartum (Kuhn et 
al., 1997). Various factors appear to affect vertical transmission throughout the gestation 
period and it seems probable that an interplay of all factors occurs, with some factors more 
determinant than others during specific periods. For instance, factors protecting against in 
utero infection may be less efficient against delivery or breast-feeding transmission. A 
general and global strategy concerning all known factors must be used to prevent vertical 
transmission (Bongertz, 2001). A greater understanding of the role played by various risk 
factors for HIV-1 infection is crucial to designing new preventive and therapeutic strategies. 
The risk of prepartum transmission depends on exposure of the fetus in utero to free virus or 
to HIV-infected maternal cells (Mittleman and Shearer, 1996), the risk of which is likely to be 
very high (Matt and Roger, 2001). Relatively few maternal cells are thought to enter the fetal 
circulation during gestation under normal circumstances. However, HIV-1 is known to 
infect cells within the placenta (Kesson et al., 1993). Intrauterine infection has therefore been 
suggested as a risk factor for mother-to-child transmission (Kuhn et al., 1999).  
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Certain conditions of delivery such as premature birth, low birth weight, early placental 
rupture or placental membrane inflammation seem to be related to increased risk of vertical 
transmission (Bongertz, 2001). Cesarean delivery is associated with a significant decrease in 
perinatal HIV transmission, from 55% to 80% (Welles et al., 2000). This result is likely to 
hold only for women with a sufficiently high viral load, since the transmission rate for 
women with undetectable viral loads is already low.  
To avoid postpartum transmission, breastfeeding by HIV-infected women is not 
recommended because it is associated with an additional 15-20% risk of transmission of 
HIV-1 (Nduati et al., 2000).  
In conclusion, it is now clear that the risk for vertical transmission and subsequent immune 
suppression depends on multiple factors in both the virus and the host (Singh and Spector, 
2009). Several factors have been proposed to influence the risk of mother-to-child 
transmission and disease progression in children infected with HIV. These include high 
maternal viral load at birth (Shearer et al., 1997) and viral phenotype (De Rossi et al., 1997).  
4.2 Maternal viral load and vertical HIV transmission 
Higher maternal virus load is associated with an increase in the vertical HIV transmission 
rate (Cao et al., 1997; Rogers and Shaffer, 1999), although the correlation is modest. Treating 
HIV-infected pregnant women with the antiretroviral drug zidovudine was associated with 
a reduced rate of transmission (Connor et al., 1994), though the drug may not produce this 
effect by reducing viral load: a recent study found that zidovudine reduced vertical 
transmission despite a minimal effect on viral load (Melvin et al., 1997; Newberry and 
Kelsey, 2003). Whatever the mechanism of zidovudine, it remains generally true that risk of 
vertical transmission can be minimized if therapies known to reduce the patient's serum and 
vaginal viral loads are continued during pregnancy. Indeed, even if the risk of mother-to-
child transmission is very low in women with low viral load, vertical transmission has been 
reported in women with all viral load levels (Newberry and Kelsey, 2003).  
4.3 Viral phenotype and vertical HIV transmission 
Viral phenotype is also a risk factor for vertical transmission. Genetic variability within HIV-
1 is generated by reverse transcriptase during replication of the viral genome. The enzyme 
lacks 3’ proofreading ability. Consequently, rapid replication result in a high degree of virus 
polymorphism (Wei et al., 1995). This variability among virus phenotypes may allow the 
appearance of viral escape forms, so-called because they can escape the immune response 
(Pillay and Phillips, 2005), as well as allow the emergence of viral strains resistant to 
antiretroviral therapy (Biggar et al., 2002). Both of these viral forms may then be transmitted 
to the child. Viral phenotype is also a risk factor independent of reverse transcriptase: the 
frequency of appearance of resistance mutations depends on the HIV subtype (A, C and D) 
(Kantor et al., 2002).  
4.4 Cytotoxic T lymphocytes (CTLs) and vertical HIV transmission 
Various components of the immune system affect viral replication and therefore may 
participate in vertical transmission. Induction of suppressor and cytotoxic T lymphocytes 
(CTLs) and neutralizing antibodies (NAbs) are considered fundamental for a protective 
immune response against HIV (see Section 6) and have also been implicated in protection 
against vertical transmission (Bongertz, 2001).  
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Class I-restricted CTLs exert significant immune pressure on HIV-1 and may be an 
important factor in mother-to-child transmission (Pillay and Phillips, 2005). Recognition of 
peptide-MHC complexes by CTL receptor triggers a response that ends in the recognition 
and lysis of HIV-infected cells by CTLs, which blocks the propagation of HIV-1. There is an 
inverse correlation between plasma RNA viral load and levels of HIV-specific CTLs in 
patients infected by HIV-1 (Ogg et al., 1998). CTLs detect viral antigens that have been 
processed intracellularly. Peptides are cleaved and presented on the cell surface by MHC I 
molecules. Recognition of the peptide-MHC complex triggers a response that results in lysis 
of the infected cell. HIV-1-specific CTLs seem to contribute to the control of HIV-1, as do 
certain HLA class I alleles that encode the MHC molecules required for the presentation of 
these peptide fragments to CTLs. In particular, HLA-B27 and HLA-B57 are predicted to be 
involved in the control of both HIV infection and AIDS progression, while HLA-B35 is 
associated with rapid disease progression (Kaslow et al., 1996; Carrington et al., 1999).  
The impact of CTL responses on vertical transmission in HIV-infected pregnant women has 
been investigated since the 1990s (Matt and Roger, 2001). CTL activity in the maternal 
peripheral circulation is similar to that in the non-pregnant state and CTLs can appear early 
in infants, where their presence correlates with slow progressive HIV disease (Pillay and 
Phillips, 2005). Consequently, an indirect role for CTLs in mother-to-child transmission has 
been proposed (Polycarpou et al., 2002). Moreover, levels of CTL precursor frequencies 
specific for pol and nef HIV variants were more frequently found during pregnancy in non-
transmitting mothers than in transmitting ones (Jin et al., 1998). Because nef is transcribed 
early during the replication of HIV, a strong nef-specific CTL response may be important for 
the clearance of HIV soon after viral protein expression, thereby limiting further viral 
transmission. Interestingly, a nef-specific CTL response has also been observed in uninfected 
children born to HIV-positive women (De Maria et al., 1994). Importantly, CD4+ T cells are 
critical in maintaining CTL activity against HIV-1 (Kalams and Walker, 1998), and their 
importance in vertical transmission has also been demonstrated (Plaeger et al., 1999).  
Although it induces the CTL response, the virus cannot always be completely controlled. 
This is often due to mutations in viral peptides that allow virus to escape CTL recognition 
via MHC class I molecules (Pillay and Phillips, 2005). Vertical transmission of HIV-1 may 
imply that the transmitted virus is a CTL escape form; such forms have indeed been 
detected in infants (Pillay and Phillips, 2005). Mothers share at least 50% of their HLA alleles 
with their children but children may still respond differently than their mothers, depending 
on their HLA and their concordance with the mother’s alleles. For example, if the mother 
and the child share the protective HLA-B27, transmission of virus to the child will be 
effective: since the virus is adapted to escape B27 recognition, the allele will not confer 
protection from HIV-1 on the child (Goulder et al., 2001). In contrast, if the child inherits the 
HLA B27 allele from the father, the child will be able to generate a strong response to viral 
epitopes. The viral escape mutation can be maintained in the HIV-1 population if it does not 
imply a fitness cost; if it does, the mutation will revert in the absence of immune pressure 
(see Section 6) (Allen et al., 2004).  
4.5 Neutralizing antibodies (NAbs) and vertical HIV transmission 
Although the CTL response is an important mediator of protective immunity and has been 
implicated in controlling virus load, the maternal CTL response is insufficient to determine 
the fate of HIV vertical transmission (Matt and Roger, 2001). Several other factors are 
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important, including the ability of the mother to generate antibodies, particularly 
neutralizing antibodies (NAbs) that are able to block viral replication. In individuals 
infected with HIV-1, high levels of antibodies against the envelope viral proteins gp120 and 
gp41 are synthesized (Fig. 2). However, these antibodies do not seem to be very effective 
against HIV since they are not able to neutralize it in vitro. This is probably due to the high 
degree of glycosylation of these proteins (Reitter et al., 1998; Wyatt et al., 1998; Rudd et al., 
2001). Nevertheless, there are other Nabs that can be generated rapidly in primary HIV 
infection (Richman et al., 2003). NAbs are thought to protect against vertical transmission, 
since they can pass through the placental barrier, they have been detected in mother’s milk, 
and they are believed to be present during delivery (Bongertz, 2001). In general the presence 
of high amounts of NAbs is correlated with chronic, non-progressive disease (Pillay and 
Phillips, 2005).  
High levels of NAbs are detected during pregnancy. Nevertheless, whether maternal NAbs 
and maternal humoral immunity in general play a role in vertical HIV transmission remains 
controversial. Several early reports indicated an association between maternal NAbs and 
protection against vertical transmission (Rossi et al., 1989; Devash et al., 1990; 
Louisirirotchanakul et al., 1999), but these observations were not confirmed (Bal et al., 1996; 
Hengel et al., 1998). Since selection for escape HIV-1 variants occurs during transmission, it 
is possible that non-neutralized variants are transmitted to the infant (Okamoto et al., 1997). 
Moreover it appears that the timing and mechanism of NAb activity during vertical 
transmission is important. A strong local NAb response is probably effective at controlling 
HIV multiplicity during pregnancy, but ineffective at blocking transmission of HIV-1-
infected cells (Bongertz, 2001).  
4.6 HIV coreceptors and vertical HIV transmission 
In this section of the chapter, we will briefly describe non-MHC genetic factors that 
influence vertical transmission and then we will focus on the association between HLA 
polymorphism and vertical transmission. 
In addition to CD4, HIV-1 uses other coreceptors to enter the T cell, and these have been 
identified as chemokine receptors (Cairns and D'Souza, 1998). The CCR5 chemokine 
receptor is mainly used by non-syncytium-inducing (NSI) HIV-1 strains, whereas 
syncytium-inducing strains use the SDF1 chemokine receptor CXCR4. Some strains also use 
additional chemokine receptors such as CCR2 and CX3R1 (Cairns and D'Souza, 1998; Singh 
and Spector, 2009). A mutant CCR5 allele carrying a 32-bp deletion (CCR5-Δ32) was 
identified independently by several groups, and found to cause the loss of coreceptor 
activity (Dean et al., 1996; Liu et al., 1996; Samson et al., 1996). This allele has been identified 
as a natural polymorphism that reduces the risk of acquiring HIV-1 infection (McNicholl et 
al., 1997). Nevertheless, several studies about the role of this allele in mother-to-child 
transmission showed that CCR5-Δ32 heterozygosity alone does not protect against vertical 
transmission (Matt and Roger, 2001). Conversely, another genetic polymorphism, CCR5-
59356-T, was strongly associated with a higher rate of vertical transmission of HIV-1 among 
black infants (Kostrikis et al., 1999).  
The CCR2-64-I allele was shown to confer long-term protection in adults (Smith et al., 1997), 
but it was not associated with mother-to-child transmission (Mangano et al., 2000). A genetic 
polymorphism in the untranslated region of the SDF-1 gene in mothers was associated with 
increased risk of vertical transmission of HIV-1, mainly through breastfeeding (John et al., 
2000).  
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4.7 MHC and vertical HIV transmission 
Although vertical transmission of HIV-1 has been correlated with a wide range of viral and 
maternal features, the factors affecting this transmission have yet to be definitively 
identified (Matt and Roger, 2001). Efforts to explain why only a proportion of children born 
to HIV-infected mothers become infected have led to the discovery of important host genetic 
and delivery variables. One of the most relevant genetic factors is the MHC system, which, 
as mentioned above, plays a critical role in HIV transmission in both horizontal and vertical 
transmission. Since the 1990s, it has been known that certain HLA types are more 
susceptible or resistant to HIV-1 infection. In principle, HLA genotype may influence 
disease susceptibility in utero by affecting CTL response or other immune responses. HLA 
association with mother-to-child transmission has been found with class I, class II, and non-
classical HLA alleles. A serologic HLA typing study of Scottish infants by Kilpatrick et al. 
(Kilpatrick et al., 1991) found that specific HLA haplotypes were associated either with 
protection or increased susceptibility to HIV-1 vertical transmission. In particular, the HLA-
A3-B7-DR2 haplotype was associated with protection against HIV-1 infection, whereas the 
HLA-A1-B8-DR3 haplotype was associated with HIV-infected children. RFLP HLA-DRB1 
analysis performed by Greggio et al. showed that certain DRB1-13 allele subtypes were 
associated with protection against vertical transmission of HIV-1 (Greggio et al., 1993). 
These findings were subsequently confirmed using molecular HLA typing methods. The 
HLA-DR2 allele (DRB1*1501) was not associated with mother-to-child transmission of HIV-
1, while the HLA-DR3 (DRB1*03011) allele was positively associated with the occurrence of 
HIV-1 infection among American Caucasian infants (Winchester et al., 1995).  
Among infected infants, MHC alleles can influence disease progression. For instance, the 
HLA DR3 haplotype (DRB1*0301-DQA*0501-DQB1*0201) was associated with the 
development of severe clinical manifestations and death in African-Americans, DPB1*0101 
was associated with survival to at least two years of age, and DQB1*0604 was related with 
increased risk of infection (Just et al., 1995a). A study with Spanish children in Catalonia 
confirmed the association between the DQB1*0201 allele and severe clinical outcomes, but 
found that the DRB1*0301 allele showed a tendency to protect against disease progression 
(Just et al., 1996). The differences observed between these studies may be explained by 
ethnic differences among the children studied (Winchester et al., 1995; Just et al., 1996). 
Indeed, ethnicity appears to be an important variable for interpreting the effect of HLA 
alleles. For instance, the DRB1*13011 allele is significantly associated with a diminution in 
vertically transmitted HIV-1 infection in African-American children but not in American 
Caucasian children. Moreover, other HLA DR13 alleles (DRB1*1301, *1302, *1303) are 
associated with protection against HIV-1 transmission in African-American but not in 
Caucasian children (Winchester et al., 1995).  
Altogether, these data suggest that the HLA DR3 haplotype is associated with both 
increased risk of vertical transmission of HIV-1 and pediatric disease progression (Just et al., 
1995b; Winchester et al., 1995), while the HLA DR13 allele is associated with protection 
against HIV-1 infection (Winchester et al., 1995). However, the HLA DR3 (DRB1*03011) and 
HLA-A2 alleles show discordant effects between African-American and Caucasian ethnic 
groups. 
These observations suggest that variations in the transport of virally encoded peptides to, or 
presentation by, MHC molecules may significantly influence the host response to HIV 
infection and mother-to-child transmission. However, the identity of the HLA alleles by 
itself does not determine risk of mother-to-child transmission. Rather, the concordance or 
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discordance of HLA alleles between mother and child seems to be a key factor for vertical 
transmission.  
HLA-G is a non-classical HLA molecule from MHC class Ib with a limited distribution in 
tissues, and it is selectively expressed in placental trophoblast cells in the maternal-fetal 
interphase (Kovats et al., 1990). HLA-G has been identified as a molecule involved in 
immune tolerance, and its main function appears to be to protect the fetus from maternal 
CTLs and natural killer (NK) cells (Hunt, Petroff et al. 2000). Because of its presence in the 
placenta, it is logical to suggest that HLA-G helps to determine vertical transmission of HIV-
1, and that certain allelic mutations in the HLA-G gene increase or decrease protection of 
infants against in utero transmission. Indeed, a correlation between HLA-G variants and 
mother-to-child transmission was found in a study by Aikhionbare et al. (Aikhionbare et al., 
2001). Discordance between mother and child for a mutation in exon 2 of HLA-G was 
significantly more common among non-transmitting than transmitting mother-child pairs. 
This suggests that mother-child pairs in which both carry the same mutation in HLA-G exon 
2 may be at higher risk of vertical transmission of HIV-1. Nevertheless, another study with a 
bigger cohort of mother-child pairs in Zimbabwe did not find any relation between mother-
child HLA-G concordance/discordance and either intrauterine or peripartum transmission 
(Matte et al., 2002). Moreover, the mutation in exon 2 of HLA-G (at codon 57) does not 
change the amino acid composition of the protein (silent mutation), so it is difficult to 
envisage how a silent mutation could have a direct influence on mother-child transmission 
of HIV-1. The significant association reported in the first study (Aikhionbare et al., 2001) 
may be attributed to their relatively small sample size. However, in more recent work, 
Aikhionbare et al. argued that the differences between the studies may be due to the 
homogeneous population in the Zimbabwe study, where 90% of the mother-child pairs 
belonged to the Shona ethnicity. They suggested that in such a homogeneous group, certain 
mutations may not play a role in disease protection, whereas they do in mixed populations. 
In addition, they identified several polymorphisms in HLA-G that may be associated with 
decreased risk of vertical transmission of HIV-1 (Aikhionbare et al., 2006).  
An important milestone is the so-called “pattern of inheritance theory,” based on the 
premise that HLA concordance between a mother and her infant can be a determinant of 
vertical transmission. A study showed that HLA class I antigen concordance between a 
mother and her child is associated with an increased risk of intrauterine HIV-1 transmission, 
whereas maternal-child HLA discordance results in protection against vertical transmission 
(MacDonald et al., 1998). This was confirmed in another study showing the association with 
HLA class I concordance, but not with HLA class II (Polycarpou et al., 2002). This was also 
shown in other studies where children who inherited one or more alleles associated with 
short-term disease progression progressed more rapidly to AIDS if they inherited the alleles 
from their fathers, but not if they inherited them from their mothers. The opposite situation 
also occurs: a protective allele may be effective in children only when it comes from the 
father and not from the mother (Kuhn et al., 2004). It has been proposed that fetal 
alloimmune responses directed against maternal HIV-infected cells or free virus bearing 
maternal MHC determinants may account for protection in some children (Mittleman and 
Shearer, 1996). Maternally derived cells carry HLA molecules on their surface, as well as 
infectious viral particles. Fetal cord blood leukocytes are able to recognize foreign maternal 
HLA and mount a strong immune response. Nevertheless, in cases in which maternal HLA 
antigens are similar or identical to fetal HLA, the fetal immune response is probably less 
potent or nonexistent (Mittleman and Shearer, 1996). This may explain why HLA 
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concordance between a mother and her child is associated with an increased risk of 
intrauterine HIV transmission. A recent study of mother-child pairs in Spain suggests that 
HLA-B35 increases transmission risk, a finding that is also consistent with the pattern of 
inheritance theory (Arnaiz-Villena et al., 2009). 
5. Other MHC-related factors that influence HIV transmission 
5.1 Innate immune response 
Although the innate immune response is an essential part of anti-viral responses, its role in 
HIV infection remains obscure (Biasin et al., 2010). Viruses are recognized by the immune 
system through receptors named “pattern recognition receptors" (PRRs) that bind to 
“pathogen-associated molecular patterns” (PAMPs), which are small pieces of the virus with 
a conserved “viral tag” that host cells identify as foreign. Viral proteins are recognized by 
Toll-like receptors (TLR) 2 and 4 in the plasma membrane, while viral nucleic acids are 
recognized by TLR 3, 7, 8 and 9, which are located in endosomal membranes. In this latter 
group, TLR7 and 8 recognize single-stranded viral RNA (v-ssRNA) from HIV. Studies on 
TLR signalling during HIV infection are scarce, even though it has been proposed that 
exposed but non-infected individuals mount stronger responses through TLR-initiated 
signalling (Biasin et al., 2010).  
There are also cytoplasmic receptors such as RIG-I-like (RLR) and nucleotide-binding 
domain, leucine-rich receptors (NIRs) that have been implicated in the recognition of 
viruses. Signals from these receptors activate the cells that express them and initiate the 
production of interferons and inflammatory cytokines, including IL-1B and IL-18, which 
determine important aspects of the adaptive immune response, such as the CTL response. 
HIV is able to disrupt both TLR and RIG-1 signalling by depleting IRF3 interferon 
regulatory factor 3 (IRF-3) (Doehle et al., 2009). Type I interferons (IFN ) are especially 
crucial in early stages of viral infections. They promote an “antiviral state” by inducing the 
expression of hundreds of target genes, so-called interferon-stimulated genes (ISGs) (Baum 
and Garcia-Sastre, 2010). Plasmacitoid dendritic cells (pDCs) are the main natural INF 
producers in vivo. This subpopulation appears to be depleted in chronic HIV infection 
(Soumelis et al., 2001).  
5.2 NK responses 
NKs are CD3+ lymphocytes and they are divided into two major subgroups, NK regulatory 
or NK effector cells, depending on the levels of expression of CD56 and CD16. These cells 
play a prominent role during viral infections because they mediate early, non-adaptive 
responses against virus, and they modulate the activity of other effector cells of the innate 
and adaptive immune system. NKs exhibit cytolytic activity against cells infected with 
viruses and they secrete anti-viral products. Their cytolytic activity appears to involve 
receptors that bind MHC class I molecules. HIV-exposed but uninfected subjects have been 
reported to have enhanced NK functions and increased IFN- and TNF- levels. During 
chronic HIV infection, NK cell cytotoxicity is reduced (Ahmad et al., 2001). 
The ability of NKs to kill virally infected cells depends on a fine balance in the relative 
expression of inactivating and activating NK receptors (NKRs). Several studies have 
addressed the relationship between NK receptors that bind to MHC molecules, and viral 
load and NK activity during HIV infection (Ahmad et al., 2001; Gaudieri et al., 2005).  
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HLA-B molecules can be classified according to the presence of the mutually exclusive 
public epitopes Bw4 or Bw6 that are shared by various MHC molecules. However, only Bw4 
is a ligand for KIRs, which are type I integral membrane glycoproteins. To date, 14 distinct 
KIR genes have been described (http://www.ebi.ac.uk.kir) (Paximadis et al., 2011). KIRs 
can have either activating or inhibitory functions. It has been shown that suppression of 
HIV-1 viremia is associated with homozygosity for HLA-Bw4. Furthermore, the Bw4-80I 
group, which has isoleucine at position 80, includes two alleles (B*57 and B*27) that are 
considered protective, as previously mentioned. KIR allele KIR3DS1, which is an activating 
receptor, binds HLA-B Bw4-80I molecules, and this binding was shown to delay progression 
to AIDS. Furthermore, coexpression of both alleles in the same individual reduces the risk of 
both infection and progression (Lopez-Vazquez et al., 2005; Boulet and Bernard 2008; Boulet 
et al., 2008).  
The involvement of HLA-B Bw4/6 epitopes in transmission from infected men to their 
female sex partners was analyzed. Compared with men who were homozygous for Bw6, 
men who carried Bw4 were about half as likely to transmit HIV-1 to their female partner 
(Welzel et al., 2007). However, a more recent study that compared men homozygous for 
HLA-Cw1 or HLA-Cw2 attributed functional differences in human NK cell activity to 
distinct KIR/HLA genotypes, independently of KIR3DL1/HLA-Bw4 interactions 
(Ahlenstiel et al., 2008). It turns out that HLA-E and HLA-G are also important in the 
regulation of NK cell responses (Tripathi and Agrawal, 2007). 
The simultaneous presence of the HLA-Bw4 epitope and both the HLA-B*57 and HLA-
Cw*18 alleles correlated with low levels of viremia in 147 HIV-infected individuals in Brazil. 
The protective effect of HLA-Bw4 depended on the presence of HLA-B*57. In contrast to 
previous studies, the HLA-Bw4 epitope bearing isoleucine at position 80 did not confer a 
protective effect in the presence of the activating KIR3DS1 allele (Da Silva et al., 2011). 
The associations most consistently observed between KIRs and HIV progression involves 
KIR3DS1 and KIR3DL. KIR and HLA class I alleles were studied in 224 South African 
mothers and their 222 infants, of whom 72 were infected and 150 uninfected (Paximadis et 
al., 2011). The frequencies of KIR2DL1 and KIR2DL3 were lower in intrapartum-
transmitting (IP-T) mothers than in non-transmitting (NT) mothers. Homozygosity for 
KIR2DL3, alone or in combination with HLA-C heterozygosity (Cw1/Cw2), was more 
frequent in IP-T mothers than in NT ones. The combination of the KIR2DL3 allele and its 
ligand, HLA-Cw1 occurred less frequently in infected infants, as did homozygosity for 
KIR2DL3 in combination with HLA-Cw1/Cw2. It is noteworthy that these effects of 
genotype were more readily detectable after stratifying the sample based on low or high 
maternal viral load. 
5.3 Chemokines 
Since the discovery of CCR5 as an HIV entry cofactor (Dean et al., 1996), researchers have 
focused on chemokines as possible restriction/susceptibility factors (Alkhatib et al., 1996). 
Thus variants or haplotypes of CCL5, CCL2-CCL7-CCL1 and CCL3 have been consistently 
associated with differential susceptibility to infection or transmission (Telenti and McLaren, 
2010). Polymorphism of chemokine receptors has, in turn, been linked to specific HLA 
alleles, such as CCR2 and HLA-B58; the latter is present in long-term survival women from 
Nairobi (Fang et al., 2004) 
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5.4 Other factors 
CTL-associated antigen 4 (CTLA4) is a member of the immunoglobulin superfamily, and is 
expressed mainly on helper and regulatory T cells. After ligand binding it transmits an 
inhibitory signal to the cell. Single-nucleotide polymorphisms in the promoter region of the 
CTLA4 gene were analyzed in relationship to viral load and time to AIDS, but no clear 
association was established (Shao et al., 2006). 
6. Contribution of HLA selection of CTL responses to HIV susceptibility or 
protection  
Here we provide an overview of an important subject that is central to the struggle to 
develop a successful CTL-based HIV vaccine (Bangham et al., 2009). CTLs, also known as 
CD8+ T cells, eliminate HIV-infected cells through the recognition of antigenic peptides 
displayed by HLA class I molecules on the infected cell surface. HIV can evade T cell 
responses by mutating epitopes that are recognized by CTLs (Phillips et al., 1991) and then 
those HIV variants or “escape mutations” are selected if they maintain the fitness of the 
virus. This is called “fixation” of the mutation and it implies that the mutation confers some 
advantage for the virus against the CTL response. Significant efforts have been made to 
obtain a complete map of HIV epitopes recognized by CTLs and antibody-producing cells 
(http://www.hiv.lanl.gov), since this mapping is essential for vaccine development.  
In general it is thought that most mutations occur in the initial phase of the infection when 
the virus is rapidly replicating and therefore is more likely to mutate. However, it appears 
that the mutations in some delayed escape variants occur later in the viral life cycle. One of 
the best documented examples of an HIV escape variant is a “gag epitope” recognized by 
the HLA-B27 molecule. Patients with HLA-B27 progress more slowly to AIDS than does the 
general HIV-infected population. Peptides that bind HLA-B27 very frequently have an 
arginine (R) at the second position. The HIV gag epitope263-272 contains such arginine that 
when mutated, is no longer recognized by T cells. This escape mutation occurs in 
approximately 50% of HLA-B27-infected individuals after several years of infection. Why 
does it not appear at the beginning of the infection? Because the escape mutation R264K 
must be preceded by a first mutation, and then it subsequently appears together with a 
third. The mutation R264K has a fitness cost and thus the mutant virus tends to revert to the 
wild-type (WT) sequence in the absence of selection (i.e. HLA-B27). This was demonstrated 
by studying HLA-B27-negative babies born to HLA-B27-positive mothers infected with 
virus carrying the R264K mutation (Goulder et al., 2001); this study found that “HLA-
mediated selective pressures on the virus in a transmitting mother-infant pair may 
undermine future HLA-mediated viral control in the child”. Later the fitness cost was 
shown to be compensated by a third mutation in a position that binds an inhibitory receptor 
on dendritic cells (DCs). This example illustrates that escape mutations can be very 
complicated events, which may explain their late appearance in the course of the infection 
(McMichael et al., 2007). 
There are well established examples of associations between expression of an HLA class I 
molecule and deviation from the consensus HIV sequence (“escape mutations”). The 
converse situation also exists, namely, association of certain HLAs with the WT or 
“preserved” sequence (Leslie et al., 2005). Therefore it was proposed that HIV-1 is adapting 
to HLA-restricted responses as a consequence of selection pressure (Moore et al., 2002; John 
et al., 2005). However, CTL escape mutants that revert following transmission to individuals 
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lacking the selecting MHC alleles have been identified. The obvious implication of these 
data is that some CTL responses can be evaded only by escape mutations that paradoxically 
reduce the replicative fitness of the virus (Leslie and Goulder, 2006). Study of the impact of 
HLA on HIV molecular evolution is further complicated by the “founder effect” of HIV 
strains (Bhattacharya et al., 2007; Klenerman and McMichael, 2007). 
The question at the moment is to what extent is HIV adapting to HLA class I molecules? 
This issue was directly addressed in an international multi-cohort study, in which nine 
cohorts from 5 different continents were pooled, allowing the analysis of more than 2,800 
subjects. They studied the HLA-B*51-restricted epitope TAFTIPSI, corresponding to 
residues 128-135 of reverse transcriptase, and they showed a strong correlation between the 
frequency of the escape mutation I135X and HLA-B*51 prevalence. Similarly, the 
frequencies of other well-defined CD8+ T-cell epitopes restricted by HLA-B*57 and HLA-
B*27 correlated with the prevalence of the restricting HLA allele in the different cohorts, 
demonstrating strong evidence of HIV adaptation to HLA at the population level 
(Kawashima et al., 2009).  
7. Summary: HLA molecules confer protection or susceptibility to HIV 
infection  
The best way to identify protection or susceptibility factors is to study exposed but 
seronegative (ESN) individuals and HIV-infected LTNPs (Miyazawa et al., 2009). There are 
several possible factors that may determine how HLA molecules condition the anti-HIV 
immune response (Fig. 2). One obvious factor is the differences in peptide-binding 
repertoires among HLA molecules, which is the logic behind grouping the alleles in clusters 
or supertypes. Another factor is that HLA-DR polymorphism affects interaction with CD4 
(Fleury et al., 1995), which implies that some HLA-DR molecules bind CD4+ lymphocytes 
more than others. Similarly, particular HLA molecules, such as HLA-B*27, HLA-B57, HLA-
B*5701 (in Caucasians) and HLA-B*5703 (in Africans), are more likely to mediate successful 
control of HIV infection by activating CTL responses (den Uyl et al., 2004). HLA B*5701 was 
found to be a clear protective factor, but the protection could not be attributed to any 
quantitative differences in the total HIV-specific CD8+ T cell response (Migueles et al., 2000). 
In the case of HLA-B27, there are reports of CTL-protective response against p24 HIV 
protein, which has a relatively low rate of mutation (den Uyl et al., 2004). HIV-infected 
chimpanzees do not develop AIDS and therefore they have been used as a model to 
understand the influence of MHC on HIV disease. The peptide-binding groove of frequent 
chimpanzee MHC class I molecules, similarly to HLA-B*27/B*57, target similar conserved 
areas of HIV-1/SIV(cpz) (de Groot et al., 2010). Interestingly HLA-B*5701 is one of the major 
alleles responsible for hypersensitivity to the reverse transcriptase inhibitor abacavir (Mallal 
et al., 2002). 
Various factors, including HLA that might confer protection or susceptibility, have been 
studied in a cohort of 30 LTNPs from Spain (Salgado et al., 2011b). For example, these 
investigators studied CCR5 and the CCL3L1 gene, which encodes the MIP1a protein, an 
inhibitory CCR5 ligand. They found the B27 and B58 supertypes, as well as certain class I 
alleles, to be protective; the B7 supertype and other class I alleles were non-protective. No 
significant association with CCR5-Delta32 was found, probably because this mutation is rare 
among Spaniards. Similarly, CCL3K1 copy number did not influence the rate of progression. 
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Protective HLA-B and -C alleles were more frequent in LTNPs, though such an association 
was not observed with HLA-A alleles. In addition to HLA-B*5701 and -B*2705, the 
investigators found HLA-Cw0102, -Cw0602 and -Cw1203. The presence of allele 
combinations such as HLA B*5701-Cw0602, HLA B*2705-Cw0102, and HLA B*3801-Cw1203 
showed the strongest association with non-progression. 
 
 
Fig. 2. Points where genetics influences HIV infection and its progression.  
Although chimpanzees are susceptible to infection with HIV-1, they do not develop AIDS. A 
similar situation occurs when they are infected with the chimpanzee simian 
immunodeficiency virus (SIVcpz). Chimpanzee class I molecules are designated Patr-A, -B 
and –C, and like those of humans, they are polymorphic. However it has been proposed that 
their repertoire has been skewed by strong selective pressure exerted by HIV or an ancestral 
retrovirus of HIV. Therefore the chimpanzee has been used as a model system to 
understand resistance to progression to AIDS. Thus, the Patr peptide-binding repertoire has 
been analyzed and compared to the binding repertoire of human HLA-B*27 and B*57, two 
HLA molecules correlated with resistance in humans (Groot et al., 2010). This work showed 
that at least one Patr molecule in the study population recognizes conserved areas of the 
Gag protein that are also recognized by B*27 and B*57. 
The mechanism of the protective effect exerted by HLA-B*58:01 was studied in South 
African individuals infected with HIV subtype-C (Chopera et al., 2011). One of the major 
conclusions of this work is that HLA-B*58:01 patients whose CTLs target the TW10 in the 
p24Gag viral epitope maintain higher CD4+ T cell numbers than those whose CTLs do not 
target that part of the epitope. However, escape mutations were detected early, as soon as two 
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weeks after infection. In addition, the escape mutations were accompanied in some cases by 
compensatory mutations that may limit the protective effect of the HLA-B*58:01 allele. 
A correlation was found between the HLA peptide-binding affinities of 95 HLA class I 
alleles and sequence conservation of targeted viral regions in 52 human viruses, including 
HIV (Hertz et al., 2011). This analysis indicates that HLA-A alleles and those HLA-B alleles 
most closely related to chimpanzee alleles preferentially target peptides from DNA viruses, 
while other HLA-B alleles generally target peptides derived from RNA viruses. This is an 
important conclusion that may at least partially explain why it is primarily HLA-B alleles 
that determine susceptibility and progression of HIV infection. 
7.1 Susceptibility conferred by HLA-B35 alleles 
Individuals positive for HLA-B35 have a greater chance of becoming infected and show 
accelerated HIV-1 disease progression. In the late 1990s, numerous HIV mutations in HLA-
B35-restricted epitopes were found (Kawana et al., 1999). Hence initial studies of 
susceptibility conferred by HLA-B35 focused on CTL responses (Jin et al., 2002). Later work 
showed that the increased risk was associated with the subset of HLA-B35 alleles known as 
B*35-Px molecules (Jin et al., 2002). Interestingly, some alleles in the alternative set of B*35 
subtypes, B*35-PY, present HIV-1 epitopes identical to those of B*35-Px molecules, yet have 
no detectable impact on HIV-1 disease outcomes. In other words, both HLA-B35 subtypes 
recognize the same HIV epitopes, implying a similar CTL response. If that is true, how can 
we explain the differences in responses in these two HLA-B35 subsets? Differences in innate 
immunity could be the underlying cause: the B*35-PY molecule B*3501 and the B*35-Px 
molecule B*3503 differ by only one amino acid and present identical HIV-1 epitopes, yet the 
B*35-Px molecule binds with greater affinity to immunoglobulin-like transcript 4 (ILT4), an 
inhibitory MHC class I receptor expressed on DCs. This binding to ILT4 is associated with 
significantly stronger DC dysfunction during in vitro functional assays (Huang et al., 2009). 
That study concludes that differential interactions between HLA class I allele subtypes and 
immune regulatory MHC class I receptors on DCs is an important determinant of the 
immune response to the HIV virus. 
Lazaryan et al. (2011) compared the effects of class I alleles in African-Americans infected 
with subtype B with those in Africans infected with subtype C. Among African-Americans, 
HLA alleles A*32, A*74, B*14 and B*45 were strongly associated with control of HIV 
infection. Furthermore, infrequent HLA-B alleles were associated with better disease 
outcome. This was consistent with a previous study by the same investigators, in which they 
found that relatively infrequent supertypes in African-Americans correlated with a better 
immunological profile. When the researchers took into account the known linkage 
disequilibrium among A, B and C alleles in their cohort, they detected that HLA-A*32 and 
A*74 were associated with favourable outcome. The protective effect of HLA-B*57 was also 
confirmed in this population, while B35 and B53 alleles were associated with poor outcome. 
These results are inconsistent with the previously described PX/PY theory (Huang et al., 
2009) (section 7.1). Lazaryan et al. (2011) found that both B*5301 (PX) and B*3501 (PY), the 
most frequent alleles in their groups, were equally disadvantageous. 
8. Hypersensitivity to anti-HIV drug treatment  
The occurrence of hypersensitivity reactions to drugs used to treat HIV infection has 
complicated HIV treatment management. Antiretroviral drugs are currently grouped into 6 
major classes:  
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- Nucleoside reverse transcriptase inhibitors (NRTIs) 
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
- Protease inhibitors (PIs) 
- Entry inhibitors, further subdivided into fusion inhibitors and CCR5 inhibitors 
- Integrase inhibitors 
Most HIV patients receive therapy that combines various drugs, known as HAART. This 
complicates the diagnosis of drug hypersensitivity. In addition, allergic reactions to anti-
HIV drugs usually occur with a delay of 1 to 6 weeks. Skin reactions are the most common 
manifestations, and they can vary from exanthema to systemic symptoms or syndromes that 
have received various names, such as drug-induced hypersensitivity syndrome (DIHS). 
Most of the drugs used to treat HIV infection produce hypersensitivity in a percentage of 
patients. We recommend to our readers an excellent recent review on the subject (Chaponda 
et al., 2011). 
Genetic factors have been shown to play a role in some of the adverse effects of these drugs, 
especially in the case of abacavir. This NRTI induces hypersensitivity that is strongly 
associated with the MHC class I HLA*5701 allele (Mallal et al., 2002), implying a significant 
genetic component. Screening for HLAB*5701 has now become part of HIV treatment 
involving abacavir and has helped prevent adverse reactions.  
9. New technologies 
Historically, studies of HLA association with HIV infection have evolved in parallel with 
advances in technology. Initially HLA determinations were performed by serology, which 
has gradually been replaced by molecular techniques. We are now in the so-called "-omics" 
era: genomics and proteomic technologies, including microarrays, next-generation DNA 
sequencing and mass spectrometry, are important for identifying molecular markers in 
complex traits (Sharon et al., 2010), such as in HIV infection. The genetics of HIV 
susceptibility will most probably include frequent and rare variants, with each type of 
variant making different contributions to the specific aspect of the disease analyzed. This 
implies that the design of the study itself is a key factor that affects the consistency of the 
results. Therefore a large number of subjects is recommended in some instances (1000 
patients and 1000 controls) (Telenti and McLaren, 2010). 
A whole-genome association study (WGAS) was performed to uncover the genetic factors 
that govern variations in viral load among individuals during the asymptomatic period of 
infection. Two polymorphisms were found, one located in an endogenous retroviral element 
occurring within the HLA-B57*01 allele, and another near the HLA-C gene (Fellay et al., 
2007). More recently, a WGAS of a cohort of 2,554 HIV-infected Caucasian individuals 
excluded a role for any gene polymorphism outside the MHC complex, including the 
chemokine receptor gene cluster on chromosome 3 (Fellay et al., 2011). Viral control was 
associated with genetic variants that map near the HLA-B and -C loci, though variants also 
exist in the MHC region. The study detected in this cohort two previously described SNPs 
(Fellay et al., 2007) and found them to be associated with HLA-B*5701 and HLA-C (Fellay et 
al., 2011). 
In a study of the association of HLA-C with HIV control, Kulkarni et al., (2011) reexamined 
the SNP -35, which lies 35 kb upstream of HLA-C (Fellay et al., 2007). This SNP was found 
to be in fact a marker of another polymorphism in the 3’-untranslated region (3'-UTR) of 
HLA-C. This polymorphism regulates the binding of a microRNA (miRNA), has-miR-148, to 
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the 3'-UTR. This binding results in relatively low surface expression of HLA-C. MicroRNAs 
are RNAs that bind to the 3'-UTR to cause post-transcriptional repression, cleavage or 
destabilization. Even more, the 3'-UTR polymorphism of HLA-C that regulates binding by 
has-miR-148 is associated with HIV control.  
Recently, the International HIV Controllers Study Group (Pereyra et al., 2010) analyzed a 
large cohort from multiple populations, comprising 974 controllers and 2,648 progressors. 
The study yielded 1,384,048 single-nucleotide polymorphisms (SNPs). In the largest group 
of 1,712 individuals of European ancestry, all SNPs that reached statistical significance were 
located in the MHC region, around class I genes. A similar clustering of SNPs occurred in 
other ethnic groups and across the entire sample population. When the HLA typing and the 
SNPs were considered together, through a process of "imputation" in which HLA type was 
inferred from a previous WGAS on diabetes, HLA B*57:01, B*27:05, B*14/Cw*08:02, B*52, 
and A*25 were identified as protective alleles, and B*35 and Cw*07 as risk alleles. These 
results are consistent with previous HLA association studies. The HIV Controllers study 
went a step further and analyzed whether the observed associations might be explained by 
the presence of specific AAs within the polymorphic positions on HLA molecules. Among a 
total of 372 polymorphic AA positions in class I and II, 286 were biallelic, accommodating 
two possible AAs, while the remaining 86 could accommodate more than two AAs. 
Interestingly position 97 was detected as the most polymorphic, with 6 alternatives. In fact, 
position 97 in HLA-B was more significant than any single SNP, and positions 67, 70 and 97, 
located in the binding groove, were better markers than any single classical HLA allele. 
Position 97 is located at the base of the binding groove and has an important contribution to 
peptide binding. Arginine is present at position 97 in HLA-B*35, a “risk molecule”, while 
protective HLA molecules, such as B*5701, B*27:05 and B*14 possess valine, asparagine and 
tryptophan, respectively. A similar analysis performed on HLA-A showed a small but 
significant contribution of position 77, while for HLA-C the results were more difficult to 
interpret. This WGAS corroborated the importance of HLA-B peptide presentation for HIV 
susceptibility (Pereyra et al., 2010).  
Novel genetic factors influencing plasma levels of HIV-RNA and cellular HIV-DNA in 605 
HIV-1-infected individuals were investigated. Most of the SNPs were located in the 6p21 
MHC region, near class I and II genes, except for two outside this region. One of them was 
located within the syndecan 2 gene (Dalmasso et al., 2008). Intriguingly, increased 
expression of syndecan isoform 1 -but not of isoform 2- has been implicated in microbial 
translocation in the gut that is associated with chronic stimulation of the immune system 
(Smith et al., 2010).  
DNA microarrays were used to analyze gene expression patterns in CD3+ T cells from 
LTNPs and controls. They found that most up-regulated genes in rapid progressors 
localized to cellular organelles and were implicated in the regulation of DNA replication, 
cell cycle progression and DNA damage response. In contrast, most genes up-regulated in 
LTNPs were located at the plasma membrane and were involved in cytokine-cytokine 
receptor interaction, negative control of apoptosis and regulation of the actin cytoskeleton. 
This suggests that progressors mainly up-regulate markers of viral replication, while non-
progressors do not (Salgado et al., 2010a).  
Proteomics is now also being used to study host genetic factors in HIV response, though 
mostly in relation to specific aspects of the disease, such as neurological damage (reviewed 
by (Zhang et al., 2010)).  
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We would like to end this chapter by mentioning new trends in research on the genetics of 
HIV disease by mentioning the role of autophagy (Blanchet et al., 2010), and the cell skeleton 
or cytoskeleton (Harmon et al., 2010) during HIV infection and replication within the cells. 
A very recent and interesting report showed that a known tumour suppressor protein, the 
cyclin-dependent kinase inhibitor p21, has an important role in inhibiting various steps of 
HIV transcription in CD4+ T cells. Elite controllers showed increased expression of p21, 
which should effectively down-regulate HIV replication. Future studies should determine 
whether individuals expressing protective alleles such as HLA-B*57 express high levels of 
p21. These studies are necessary in light of the fact that the locus of the CDKN1A gene, 
which encodes p21, is located near the MHC class I genes (Chen et al., 2010). We are certain 
that genetic factors involved in these processes will be identified as susceptibility or 
protective factors in the near future. 
 
Factor 
 
Role in HIV infection 
 
Reference (s) 
 
HLA class I 
Concordance between mother and child is 
associated with increased risk of HIV 
transmission. “Pattern of inheritance theory”.
Importance of AAs at position 97 in HLA-B 
and 77 in HLA-A molecules. HLA-B 
preferentially targets peptides derived from 
RNA viruses 
MacDonald, et al., 1998; 
Polycarpou et al., 2002; 
Kuhn et al., 2004; Pereyra et 
al., 2010; Hertz et al., 2011 
A25 Protection in disease progression Pereyra et al., 2010 
B27 
Protection. Slow disease progression. Lower 
risk of infection and slow progression in 
vertical transmission. “Pattern of inheritance 
theory”. CTL responses associated with HIV 
control 
Kaslow et al., 1996, McNeil 
et al., 1996; Yap et al., 1996; 
Goulder et al., 2001; den Uyl 
et al., 2004; Groot et al., 
2010 ; Pereyra et al., 2010 ; 
Salgado et al., 2011b 
B35 
Increase risk of infection and disease 
progression. Increased risk of vertical 
transmission. “Pattern of inheritance theory”. 
Decreased number of CD4+ T lymphocytes. 
CTL responses associated with lack of HIV 
control. DC dysfunction 
Klein et al., 1994; Carrington 
et al., 1999; Kawana et al, 
1999; Jin et al., 2002; Flores-
Villanueva et al., 2003; Liu 
et al., 2003; Arnaiz-Villena 
et al., 2009; Huang et al., 
2009 ; Pereyra et al., 2010 
B*51 
CTL responses that control HIV replication. 
Viral mutations allow HIV escape 
Kawashima et al., 2009 
B*52 Protection in disease progression Pereyra et al., 2010 
B57 
Protection. Slow disease progression. B*5701 
in Caucasians and HLA-B*5703 in Africans, 
are more likely to mediate successful control 
of HIV infection by activating CTL responses
Kaslow et al., 1996; den Uyl 
et al., 2004; Fellay et al., 
2007; Groot et al., 2010 ; 
Pereyra et al., 2010 ; Salgado 
et al., 2011b 
B57*01 Hypersensitivity to abacavir. Mallal et al., 2002 
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Factor 
 
Role in HIV infection 
 
Reference (s) 
 
B58 and B58*01
Long survival in women in Nairobi. 
Protection against HIV infection. CTL 
responses 
Fang et al., 2004 ; Chopera et 
al., 2011 
Bw4 
Protection in infection and disease 
progression. Suppression of viremia in 
homozygosis. Receptor for KIR (NK cells) 
Lopez-Vazquez et al., 2005; 
Welzel et al., 2007; Boulet & 
Bernard, 2008; Boulet et al., 
2008 
HLA-C 
Variation of viral load during asymptomatic 
period. Polymorphism at 3’UT region that 
binds microRNA decreasing its level of 
expression 
Fellay et al., 2007; Kulkarni 
et al., 2011 
Cw*04 Disease progression in Caucasian Carrington et al., 1999 
Cw*07 Risk of progression Pereyra et al., 2010 
DQB1*0201 Severe clinical outcome in children Just et al., 1996 
DR1 Kaposi’s sarcoma Klein et al., 1994 
DR3, DRB1*0301
Opportunistic infections. Risk of infection in 
American Caucasian children. 
Klein et al., 1994; 
Winchester et al., 1995 
DR13, 
DRB1*130101, 
*1302, *1303 
Protection in vertical transmission. 
DRB1*1303 associates with reduced viral 
loads 
Greggio et al., 1993; 
Winchester et al., 1995; Julg 
et al., 2010 
HLA-E Implicated in NK cells responses Tripathi & Agrawal, 2007 
HLA-G 
Discordance between mother and child for 
mutation in exon 2 has a higher frequency 
among non-transmitting mother-child pairs. 
Controversial role in vertical transmission. 
Implicated in NK cells responses 
Aikhionbare et al., 2001; 
Matte et al., 2002; 
Aikhionbare et al., 2006; 
Tripathi et al., 2007; Fainardi 
et al., 2011 
A3-B7-DR2 Protection in vertical transmission Kilpatrick et al., 1991 
A1-B8-DR3 Increased risk of vertical transmission Kilpatrick et al., 1991 
KIR2DL1, KIR2 
DL3 
Lower frequencies in intrapartum-
transmitting (IP-T) mothers than in non-
transmitting (NT) mothers 
Paximadis et al., 2011 
CCR5 (delta32), 
CCR2-64I 
Correceptor for HIV, reduced risk of 
infection. CCR2-64-I allele was shown to 
confer long-term protection in adults 
Dean et al., 1996; Liu et al., 
1996; Samson et al., 1996 ; 
McNicholl et al., 1997; Smith 
et al., 1997 
Table 2. Major factors associated with HIV infection and progression. 
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